Kratko priopćenje

https://doi.org/10.24869/psyd.2017.497

OCCURRENCE OF POST-INJECTION DELIRIUM/SEDATION SYNDROME AFTER APPLICATION OF OLANZAPINE LONG-ACTING INJECTION DURING ONE YEAR PERIOD

Suzana Uzun ; University Psychiatric Hospital Vrapče, Zagreb, Croatia; University Josip Juraj Strossmayer Osijek, School of Medicine, Osijek, Croatia
Oliver Kozumplik ; University Psychiatric Hospital Vrapče, Zagreb, Croatia; University Josip Juraj Strossmayer Osijek, School of Medicine, Osijek, Croatia
Ivan Ćelić ; University Psychiatric Hospital Vrapče, Zagreb, Croatia
Nela Pivac ; Ruđer Bošković Institute, Division of Molecular Medicine, Laboratory for Molecular Neuropsychiatry, Zagreb, Croatia
Ninoslav Mimica ; University Psychiatric Hospital Vrapče, Zagreb, Croatia; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Sažetak

Introduction: The aim was to report the occurrence of after application of olanzapine long-acting injection (OLAI) in patients with schizophrenia during one year period.
Subjects and methods: During one year period, OLAI was applied to 30 patients with schizophrenia (18 men, 12 women) who were non-adherent to previous treatment with oral olanzapine. Patients were 20-58 years of age (39 years old on average), diagnosed with SCID based on DSM-IV-TR criteria. Patients received OLAI in dosage between 210-405 mg (287±62 (mean ± SD)) every 2-4 weeks.
Results: Out of 30 patients that received OLAI, 29 patients improved significantly without side-effects, and one patient developed post-injection delirium/sedation syndrome (PDSS). The patient's somatic condition stabilized and treatment with OLAI was discontinued due to the PDSS.
Conclusion: The occurrence of PDSS is not common and when it occurs, in our experience, it was reversible.

Ključne riječi

olanzapine; patients; post-injection delirium/sedation syndrome; schizophrenia; treatment

Hrčak ID:

190611

URI

https://hrcak.srce.hr/190611

Datum izdavanja:

4.12.2017.

Posjeta: 1.406 *